Why Dr Reddys Share Price is Rising

The pharma sector in India is a vital part of the country's economy. It is one of the largest suppliers of generic medicines globally. The industry is known for its innovation and affordability, contributing to healthcare worldwide.

With a growing focus on R&D and exports, Indian pharma companies play a key role in global healthcare solutions.

Among these, Dr Reddy's Laboratories is a prominent name. The company specialises in producing a wide range of pharmaceutical products. It focuses on generics, biosimilars, and active pharmaceutical ingredients (APIs).

Dr Reddy's serves markets in India, the US, and several other countries. The company is recognised for its emphasis on innovation and high-quality healthcare solutions.

Recently, Dr Reddy's share price has gained significant attention. Over the last five days, its share price surged 7.6%.

Let's explore the factors driving up Dr Reddy's share price.

Positive Outlook

Dr Reddy's Laboratories is gaining attention due to its strategic focus on long-term growth and emerging markets.

Despite underperforming against the Nifty Pharma Index over the last 1-5 years, international brokerage firms have upgraded their price targets for the company.

This upgrade indicates confidence in Dr Reddy's ability to overcome near-term hurdles and leverage future growth opportunities.

The stock's recent challenges stem from heavy dependence on gRevlimid, whose sales are expected to decline by FY26, and increased overheads linked to rising investments in R&D, biosimilar trials, and manufacturing upgrades. These investments have led to temporary pressure on profit margins.

For instance, earnings before interest, tax, depreciation, and amortisation (EBITDA) margins are forecasted to remain slightly under the pressure through FY27.

However, analysts project accelerated earnings growth starting FY28 as new revenue streams such as GLP-1 APIs, biosimilars, and injectables mature.

Dr Reddy's is expanding its manufacturing infrastructure, focusing on high-demand areas like peptide APIs and injectables.

It is also poised to capitalise on low-competition injectable launches in the US and growth in emerging markets, including India and Canada. The Canadian semaglutide market, estimated at US $ 1-1.5 billion (bn), offers a significant opportunity post the 2026 patent expiry.

The company's ability to transition from near-term challenges to medium and long-term growth is driving investor optimism.

Strategic investments, new market opportunities, and innovative initiatives position Dr Reddy's for sustained growth, contributing to its recent share price surge.

What Next?

Dr Reddy's is focusing on expanding its biosimilar portfolio, targeting launches like denosumab in FY26 and a high-value biosimilar abatacept by early 2027.

It is also accelerating efforts to scale production of GLP-1 APIs and injectables, leveraging its in-house capabilities to tap into emerging global markets.

The company is exploring opportunities to expand its reach in under-penetrated geographies, aiming to establish a stronger global presence. It plans to ramp up new product launches across India, North America, and Europe, aiming to achieve a first-to-market advantage for several pipeline drugs.

Additionally, it is enhancing infrastructure, particularly in manufacturing and R&D, to strengthen its presence in high-demand therapeutic areas.

Strategic partnerships, such as the one with Nestle, are expected to unlock growth in consumer healthcare. Dr Reddy's is also actively expanding its digital therapeutics segment, integrating advanced technologies to enhance patient outcomes.

The company is also working on optimising its supply chain to ensure faster delivery and enhanced availability of critical products. Moreover, strategic investments in new manufacturing technologies are expected to boost efficiency and reduce production costs in the coming years.

The company continues to strengthen its supply chain to ensure seamless product launches in multiple geographies. Dr Reddy's is prioritising the development of advanced digital therapeutics to enhance patient care and streamline treatment processes.

It's also leveraging its strong research capabilities to create differentiated products in oncology and other high-value therapeutic segments. By increasing its focus on licensing agreements, the company is accelerating market access for its key products in emerging regions.

How Dr Reddys Share Price has Performed Recently

In the past five days, Dr Reddys share price is up 6.9%. In the last month, it has rallied 12.5%.

In 2024, so far it has rallied 15.5%. Additionally, it surged 20.6% in the last year.

The stock touched its 52-week high of Rs 1,420.2 on 21 August 2024 and a 52-week low of Rs 1,094.9 on 21 December 2023.

About Dr Reddys

Dr Reddy's Laboratories is an Indian multinational pharmaceutical company based in Hyderabad. The company was founded by Kallam Anji Reddy, who previously worked as the mentor of the institute Indian Drugs and Pharmaceuticals.

D. Reddy's manufactures and markets a wide range of pharmaceuticals in India and overseas. It began as a supplier to Indian drug manufacturers, but it soon started exporting to other less-regulated markets.

This had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the US Food and Drug Administration (FDA).

To know more about the company, check out the Dr Reddys Laboratories fact sheet and quarterly results on our website.

You can also compare Dr Reddys Laboratories with its peers:

Dr Reddys Laboratories vs Ortin Labs

Dr Reddys Laboratories vs Alkem Laboratories

Happy Investing.

To know what's moving the Indian stock markets today, check out the most recent share market updates here.

Disclaimer: This article is for information purposes only. It is not a stock recommendation and should not be treated as such. Learn more about our recommendation services here...